Joe Y Chang

Endowed Texas 4000 Distinguished Professor and Director, Stereotactic Ablative Radiotherapy Program, MD Anderson Cancer Center

[Joe Y Chang @JoeChangMD]

I am honored to be invited to give a plenary presentation at the XXIII National Congress #SEOR2026, which is being held today in the beautiful city of Alicante, Spain. The meeting is well organized by Dr. @drjavierserrano @SEOR_ESP and the food is amazing!

[Advances, an ASTRO Journal @Advances_ASTRO]

Can 3 Gy help osteoarthritis pain?

In this US retrospective series, LDRT 0.5 Gy x 6 improved mean Numeric Rating Scale pain scores from 7.3 to 2.6 at ~12 weeks, with 79% achieving a clinically meaningful ≥2-point reduction.

Low burden.

Noninvasive.

Interesting signal for selected patients with persistent OA pain.

#OncTwitter #RadOnc

[Joe Y Chang @JoeChangMD]

For sure, we need to know more about the brain, the anatomy, functions and dose response for each specific structure. Patients survive longer, have more recurrence over years or decades and brain metastasis becomes more complex now.

[giuseppe Minniti @gminniti2012]

Dose–volume effects link multiple cerebral substructures to cognitive decline. Neurocognitive toxicity reflects distributed network injury beyond the hippocampus.
@ESTRO_RT CNS focus group on @RO_GreenJournal https://t.co/JptGO6G4zu

[Joe Y Chang @JoeChangMD]

When I was a resident 24 years ago, we were taught that renal cancer is radiation resistant disease. Now, we learn that RT can achieve up to 100% local control when RT dose is appropriate.

[Shankar Siva @_ShankarSiva]

#ESTRO26 - 📣 FASTRACKII final results, median F/U of 5 years. Thank you patients, funders, investigators - #kidneycancer #kcsm
1) 100% Local Control: No local recurrences were observed at 36, 60, or 84 months.
2) 100% Cancer-Specific Survival
3) Grade 3 AEs remain at 10%

[Joe Y Chang @JoeChangMD]

Histology matters and SABR dose matters.

[Shankar Siva @_ShankarSiva]

📣 #ESTRO26 - @UmbertoRicardo e2irradiate @EORTC prospective OLIGOCARE registry of SABR for oligomets. ~2500 patients, ~3500 mets.
➡️ local failure 5% at 1 year and 11% at 3 years
➡️ Colorectal cancer has higher risk of progression
➡️ minimum PTV dose correlated with outcome

We should aim to deliver high quality SABR to optimise control! #radonc

[TLC Conference @TLCconference]

A heartfelt thank you to our outstanding chairs, Drs. @StephenVLiu and Tina Cascone, and to every single faculty member, attendee, and sponsor who helped make #TexasLung26 such a success. This year’s conference was truly our best yet, packed with meaningful discussions, wonderful energy from start to finish, and a shared passion to improve care and outcomes for patients. SAVE THE DATE: April 8-10, 2027 in Austin, TX! https://t.co/BVU3cZwIQ5 Here’s a highlight video capturing the magic 🫁

@dapattmd @karenkellymd @christine_lovly

[SEOR.es @SEOR_ESP]

El XXIII Congreso Nacional #SEOR2026 contaremos con la participación del Prof. @JoeChangMD en la sesión magistral: Evidence for SBRT and Proton Therapy in Lung Cancer.

Alicante | 📅 3–5 junio 2026

https://t.co/02ldhpyvBX #SEOR2026 #OncologíaRadioterápica #Protonterapia

[Joe Y Chang @JoeChangMD]

More than 1/3 of our clinical practice is re-RT. The challenges include how to precisely calculate composite biological effective dose and time-dependent repair factor for each organ。

[CA: A Cancer Journal for Clinicians @CACancerJournal]

Reirradiation (#reRT) offers renewed hope for cancer recurrence—but comes with serious risks. Precision techniques, advanced imaging, and multidisciplinary care are essential.

Don't miss this definitive review on this evolving treatment️:
🔗 https://t.co/T41ik4rEsa

@OncoAlert

[Stephen V Liu, MD @StephenVLiu]

Reflecting back on such a memorable #TexasLung26 - engaging discussions across so many topics. Grateful to all who were a part of it - and for the community, the chance to sit with friends, old and new.

Please join us for #TexasLung27 April 8-10, 2027 at Austin City Limits!

[OncoDaily Lung @OncodailyLung]

🫁 𝟮𝟬 𝗣𝗼𝘀𝘁𝘀 𝗬𝗼𝘂 𝗦𝗵𝗼𝘂𝗹𝗱𝗻’𝘁 𝗠𝗶𝘀𝘀 𝗙𝗿𝗼𝗺 𝗧𝗲𝘅𝗮𝘀 𝗟𝘂𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝟮𝟬𝟮𝟲

OncoDaily Lung followed the key conversations from Texas Lung Cancer Conference 2026 and gathered 20 standout posts from experts across thoracic oncology.

🔹 What stood out
• Important clinical debates
• New research perspectives
• Expert insights from leading voices
• Real discussions shaping lung cancer care

🔬 From stage III NSCLC and adjuvant therapy updates to small cell lung cancer and multidisciplinary decision-making, this meeting reflected where the field is moving next.

📌 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗽𝗼𝘀𝘁𝘀 𝗳𝗲𝗮𝘁𝘂𝗿𝗲𝗱 𝗯𝘆 𝗢𝗻𝗰𝗼𝗗𝗮𝗶𝗹𝘆 𝗟𝘂𝗻𝗴.
https://t.co/5i9Jg2mG7l

@DrewMoghanaki @JoeChangMD @heidi_onda @BenCreelan @lungoncdoc @jennifermarksmd @NarjustFlorezMD @chulkimMD @BalazsHalmosMD @ipreeshagul @KCargillMDPhD @ClayReedMD @yajur_arya @Latinamd @StephenVLiu @drshieldsmd

#LungCancer #TLC #NSCLC #OncoDaily #Oncology #cancer

[Joe Y Chang @JoeChangMD]

With the development of biology-based immunotherapy and targeted treatment, both radiotherapy technology and surgical techniques have significantly improved and much more effective. We are soldiers—army, navy, and air force—fighting cancer together to save lives. We may compete sometimes, but we collaborate much more. We share the same enemy: lung cancer.

[Joe Y Chang @JoeChangMD]

Proud to be part of RT team!

[OncoDaily @oncodaily]

@DrewMoghanaki @SalmaJabbour1 @JoeChangMD @StephenVLiu @finn_corinne @_ShankarSiva We would like to inform you that your post has been published on OncoDaily. Thank you for sharing.
https://t.co/niNbcCAaoS

[Joe Y Chang @JoeChangMD]

Texas lung cancer day 2: What is the role of radiotherapy vs. surgery in stage III NSCLC in the era of IO? In the debate about RT @SalmaJabbour1 vs. surgery @BrendonStilesMD, RT won in the case of T4 N2M0 NSCLC.

Representatives from RT and Surgery did a great job inspiring lung cancer colleagues about optimizing local TX with novel systemic TX. Ultimately, we need to answer the question of what we can/should offer to our patients, including our family members.

Congratulations on a very successful @IASLC @TLCconference

[Joe Y Chang @JoeChangMD]

@TLCconference day 2: What is the role of radiotherapy vs. surgery in stage III NSCLC in the era of IO? In the debate about RT @SalmaJabbour1 vs. surgery @BrendonStilesMD, RT won in the case of T4 N2M0 NSCLC.

Representatives from RT and Surgery did a great job inspiring lung cancer colleagues about optimizing local TX with novel systemic TX. Ultimately, we need to answer the question of what we can/should offer to our patients, including our family members.

Congratulations on a very successful @IASLC

[Joe Y Chang @JoeChangMD]

Texas Lung Cancer Conference is being held in the state capital, Austin, at a renowned music hall.

Honored to be invited to participate this exciting event with deep discussions about cutting-edge innovations in lung cancer.

[Joe Y Chang @JoeChangMD]

Radiotherapy is traditionally associated with cancer treatment, but its potential applications in neurological and psychiatric disorders like Alzheimer's disease, drug addiction, severe depression and schizophrenia are emerging areas of research.

[Evan Thomas MD/PhD @EvanThomas84]

I am thrilled to announce that Renaissance Institute completed the initial phase of its first course of LDRT for an #Alzheimers patient today.

The patient began the treatment course with a MOCA of 15, complete anosmia & ageusia, and A&Ox1.

By the end of Renaissance-modified treatment fractionation, the patient had recovered their sense of taste, was A&Ox4, able to remember my staff’s names, and MOCA improved to 19.

We look forward to opening this new & innovative fractionation scheme in the upcoming LDRT-MIND trial.

#radonc #neurology #dementia

[Joe Y Chang @JoeChangMD]

Optimized radiotherapy (indications, timing, target, dose regimens, technology) is crucial in metastatic lung cancer.

[Stephen V Liu, MD @StephenVLiu]

Radiotherapy in stage IV NSCLC has typically played a palliative role - but can we leverage the cytoreductive power of radiation to disrupt the biologic evolution of lung cancer and delay or prevent resistance? Encouraging evidence emerging in EGFR mutant NSCLC.

[Joe Y Chang @JoeChangMD]

@CJTsaiMDPhD @NRGonc @CDNCancerTrials @DrMengWelliver @DrewMoghanaki @DrAlexLouie @JAMRadOnc @DrAryaAmini @HoudaBahig @IyengarPuneeth @KHigginsMD @JeffBradleyMD @SBRT_CR There is an issue that LCT cohort doesn’t allow to switch systemic therapy but the control arm allows it. If I am patient, I would prefer to have LCT + more effective systemic treatment if available.

[Joe Y Chang @JoeChangMD]

@PhilosopherMD1 We need more well designed RT clinical studies

[Joe Y Chang @JoeChangMD]

Compared with how much we invested in radiotherapy, I think that NIH should fund more RT based research projects since we don’t have enough support from industry.

[Jia (Jenny) Liu MD PhD @JiaJennyLiu]

The TIGIT catastrophe‼️
30 agents
220 trials
~50,000 patients
>$3B+ invested

0 approvals.

This is herding in drug development.
In BMJ Oncol we examine why it happens, the hidden costs, and what needs to change.
It’s already happening again in ADCs...
🔗:https://t.co/dvbS49jGkF